In fact, LOH of chr22 or chr22q was a ubiquitous event observed in all tumors within our cohort and is likely the most common mechanism for a second hit in SMARCB1 in patients with rhabdoid tumor predisposition syndrome (i. e., germline SMARCB1 mutation). This evidence concerns the gene SMARCB1 and familial rhabdoid tumor.